CD8+ Cell Subsets of LTS and Progressors
| CD8+ Cell Marker (%) . | Long-Term Survivors . | Progressors . | HIVSeronegative Donors . | PValue* . |
|---|---|---|---|---|
| CD28 | 37 ± 9† | 35 ± 17 | 55 ± 16 | .34 |
| CD38 | 62 ± 14 | 96 ± 11 | 65 ± 10 | <.01 |
| HLA-DR | 54 ± 15 | 67 ± 17 | 19 ± 8 | .057 |
| CD45RO | 61 ± 10 | 66 ± 10 | 42 ± 15 | .29 |
| CD45RA | 56 ± 15 | 53 ± 9 | 74 ± 11 | .48 |
| CD57 | 52 ± 14 | 48 ± 15 | 20 ± 8 | .70 |
| CD62L | 32 ± 11 | 41 ± 13 | 56 ± 11 | .16 |
| CD26 | 15 ± 7 | 20 ± 13 | ND | .61 |
| CD25 | 3 ± 3 | 3 ± 2 | 3 ± 2 | .72 |
| CD122 | 34 ± 18 | 52 ± 27 | 52 ± 20 | .14 |
| CD8+ Cell Marker (%) . | Long-Term Survivors . | Progressors . | HIVSeronegative Donors . | PValue* . |
|---|---|---|---|---|
| CD28 | 37 ± 9† | 35 ± 17 | 55 ± 16 | .34 |
| CD38 | 62 ± 14 | 96 ± 11 | 65 ± 10 | <.01 |
| HLA-DR | 54 ± 15 | 67 ± 17 | 19 ± 8 | .057 |
| CD45RO | 61 ± 10 | 66 ± 10 | 42 ± 15 | .29 |
| CD45RA | 56 ± 15 | 53 ± 9 | 74 ± 11 | .48 |
| CD57 | 52 ± 14 | 48 ± 15 | 20 ± 8 | .70 |
| CD62L | 32 ± 11 | 41 ± 13 | 56 ± 11 | .16 |
| CD26 | 15 ± 7 | 20 ± 13 | ND | .61 |
| CD25 | 3 ± 3 | 3 ± 2 | 3 ± 2 | .72 |
| CD122 | 34 ± 18 | 52 ± 27 | 52 ± 20 | .14 |
*P values obtained upon comparison of statistical significance between LTS and Progressors using the Mann-Whitney U test. Bold numbers indicate that the value is considered statistically significant.
Mean percentage of CD8+ lymphocytes ± SD.